Clinical trials: Glucose Metabolism
Prediabetes, Overweight , Obesity
Exercise, Chronotype, and Prediabetes
The goal of this clinical trial is to find out whether exercising at the right time of day, based on a person's natural body clock, leads to greater health benefits in people living with prediabetes.
- Trial name
- NCT07389005
- Testing
- Timing of exercise, Control
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- German Diabetes Center
Type 2 Diabetes
Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients
The purpose of this study is to assess safety and tolerability of AZD6714 after single ascending oral doses in healthy male subjects and type 2 diabetic patients.
- Trial name
- NCT00886366
- Testing
- AZD6714
- Where
- Sweden
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Registry-based Randomized Controlled Trial in Type 2 Diabetes With Cardiovascular Risk Factors (REMATCH)
Glycemic control is a mainstay of diabetes management to reduce the risk of microvascular complications and cardiovascular outcomes in people with type 2 diabetes (T2D).
- Trial name
- REMATCH (NCT06627322)
- Testing
- Dual-combination therapy, Triple-combination therapy, Dexcom G7, Pasta
- Where
- 2 sites in South Korea
- Volunteers
- 5,950 people
- Sponsor
- Kyu Chang Won
Diabetic Foot, Health Behavior
Manipulating Narrative Presentations of Information to Encourage Good Foot Care Practice in People With and Without Diabetes Mellitus
The study explores the role of health messages (narrative, non-narrative vs. control condition [no message]) to enhance good foot care practices among people with diabetes and the general population.
- Conditions
- Diabetic Foot, Health Behavior, Foot Diseases
- Trial name
- NCT04623151
- Testing
- Online leaflet about foot care
- Where
- United Kingdom
- Volunteers
- 452 people, healthy volunteers welcome
- Sponsor
- University of Chichester
Type 2 Diabetes Mellitus, Mild Cognitive Impairment
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
This is an investigator-led prospective, randomized, open label, parallel study to explore and evaluate the therapeutic effects of Liraglutide, Empagliflozin and Linagliptin on the cognitive function in T2DM patients with mild…
- Trial name
- LIGHT-MCI (NCT05313529)
- Testing
- Liraglutide, Empagliflozin, Linagliptin
- Where
- 5 sites in China
- Volunteers
- 396 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Erectile Dysfunction, Stem Cells
Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes
Diabetes is a major concern in public health because of its high frequency and its negative consequences. Erectile dysfunction (ED) is present, regardless of age, in 50 to 75% of men with diabetes.
- Conditions
- Erectile Dysfunction, Stem Cells, Diabetes Mellitus, Type 1
- Trial name
- MESERIC (NCT03361631)
- Testing
- Autologous Bone Marrow derived Mesenchymal Stem Cells
- Volunteers
- 13 people
- Sponsor
- Central Hospital, Nancy, France
Dental Implant, Diabetes
Stability and Crestal Bone Changes Around Implants Placed at Crestal Versus Subcrestal Level in Controlled Type Two Diabetic Patients
The objective of this study is to assess clinically the peri implant tissues, the radiological marginal bone loss and the stability around implants placed at the crestal versus the subcrestal level in type 2 controlled diabetic…
- Trial name
- NCT05125445
- Testing
- Implants placed at bone crest, Implants placed 1mm Subcrestally
- Where
- Egypt
- Volunteers
- 22 people
- Sponsor
- Hams Hamed Abdelrahman
Healthy Volunteers
Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20
This is a single center, Phase I, open-label, single-blind (subjects blinded to the contents of each injection), 4 stage study designed to determine the PK, GD, safety, tolerability, and optimal ratio of rHuPH20 administered with…
- Trial name
- NCT00803972
- Testing
- rHuPH20, Insulin Human Injection, Insulin Lispro Injection
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Halozyme Therapeutics
Healthy, Type 1 Diabetes
Subcutaneous Administration of Lisofylline to Healthy Normal Subjects and Subjects With Type 1 Diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Autoimmune diseases happen when the immune system does not identify part of the body as belonging to it.
- Trial name
- NCT00896077
- Testing
- Lisofylline
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- DiaKine Therapeutics, Inc.
Type 1 Diabetes, Polycystic Ovary Syndrome
Prevalence of Hyperandrogenism in Type 1 Diabetes
The investigators aim to estimate the prevalence of functional ovarian hyperandrogenism [idiopathic hyperandrogenism, idiopatic hirsutism, and polycystic ovary syndrome (PCOS)] in adult patients with type 1 diabetes (T1DM) in an…
- Conditions
- Type 1 Diabetes, Polycystic Ovary Syndrome, Hyperandrogenism, Hirsutism
- Trial name
- NCT04979377
- Testing
- Clinical hyperandrogenism assessment, Total testosterone (ng/dL), A1c (%)
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Metabolic Syndrome, Obesity Hypoventilation Syndrome
Obesity-hypoventilation in Metabolic Syndrom Patients
The purpose of the study is to determined the prevalence of obesity-hypoventilation syndrome in patients with metabolic syndrom.
- Conditions
- Metabolic Syndrome, Obesity Hypoventilation Syndrome, Capnography
- Trial name
- NCT04839419
- Where
- France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- SOS Oxygene Mediterranee
Diabetes, Endothelial Dysfunction
Magnetic Resonance Imaging of Vascular Function
A major function of blood vessels is to control blood flow by dilating or constricting depending on the demand. Vascular dysfunction is a state in which blood vessels fail to carry out its normal roles such as regulating blood…
- Trial name
- NCT02206919
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Obesity
Involvement of the Gut Microbiota-brain Cross-talk in the Loss of Eating Control
Overweight and obesity are increasingly prevalent worldwide. These bodyweight disorders are closely related to deficiencies in the control of food intake.
- Trial name
- GMBTalk-Food (NCT05646901)
- Where
- Spain
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Type 2 Diabetes Mellitus (T2DM), Continuous Glucose Monitoring
Transition to Hospital Discharge in Insulinized Patients With Type 2 Diabetes Mellitus
This clinical study explores whether adding technological tools during hospital discharge can help people with type 2 diabetes who are starting insulin therapy achieve better treatment adherence and blood glucose control once…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Continuous Glucose Monitoring, CGM, Transition to Discharge
- Trial name
- TRANHOSPIN (NCT07061301)
- Testing
- Usual Care group, Technological group
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Type 1 Diabetes Mellitus
Prevention of Hypoglycaemia With Predictive Insulin Suspend Using Sensor Augmented Insulin Pump in Children
The aim of the study is to prove whether the use of the SmartGuard feature of the MiniMed system significantly reduces hypoglycemic excursions and thus provide proactive protection to the user.
- Trial name
- SportGuard (NCT02179281)
- Testing
- Medtronic MiniMed™ 640G system
- Where
- 2 sites in Israel, Slovenia
- Volunteers
- 100 people
- Sponsor
- University of Ljubljana, Faculty of Medicine
Diabetes, Hypertension
The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combined Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension
Diabetic nephropathy (DN) is the most important complication of diabetes mellitus (DM) and the most common cause of end-stage renal disease (ESRD).
- Conditions
- Diabetes, Hypertension, Proteinuria
- Trial name
- NCT00921570
- Testing
- Amlodipine, Valsartan
- Where
- Turkey (Türkiye)
- Volunteers
- 105 people
- Sponsor
- Gulhane School of Medicine
Metabolic Syndrome
The Effect of Mastiha Oil in Metabolic Syndrome
Mastiha Oil is a 100% natural product of the Mediterranean, extracted from the resin of Mastiha. Over 90 compounds have been identified in Mastiha oil, with monoterpenes exhibiting favorable effects in regulating mechanisms of…
- Trial name
- NCT04785573
- Testing
- Mastiha oil
- Where
- 2 sites in Greece
- Volunteers
- 94 people
- Sponsor
- Harokopio University
Metabolic Syndrome
The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome
Metabolic syndrome, labeled as the world's latest epidemic, is the force behind the global epidemic of Type 2 Diabetes Mellitus and Cardio Vascular Diseases.
- Trial name
- NCT00926341
- Testing
- Pioglitazone, Telmisartan
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Aligarh Muslim University
Type 2 Diabetes Mellitus, Cardiovascular Disease
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)
There are recent advances in therapies for the treatment of Type 2 Diabetes Mellitus (T2DM) which include the GLP1 analogues and the DPP IV inhibitors.
- Trial name
- LYDIA (NCT02043054)
- Testing
- Liraglutide, Sitagliptin
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University of Leicester
Diabetes Mellitus Type 1
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
The primary objective of this study is to assess the speed of absorption and onset of action of BIOD-105 and BIOD-107 and compare them to Humalog®.
- Trial name
- NCT01334151
- Testing
- Insulin LISPRO, recombinant human insulin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Biodel
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.